Pauls Matthew 4

What Happened
Pauls Matthew, a director of Pelthos Therapeutics Inc. (PTHS), sold a total of 786 shares in open-market transactions on July 2, 2026, generating proceeds of approximately $20,561. The sales consisted of 692 shares reported at $26.00 (proceeds $17,989) and 94 shares reported at $27.36 (proceeds $2,572). These were sales (not purchases) and are typically treated as routine dispositions rather than bullish insider buying.

Key Details

• Transaction date: July 2, 2026. Filing date: July 7, 2026.
• Reported share breakdown: 692 shares (reported price $26.00) and 94 shares (reported price $27.36). Total proceeds roughly $20,561.
• Execution details: The 692-share block was executed in multiple trades at prices from $25.58 to $26.24 (weighted average reported). The 94-share block was executed in multiple trades at prices from $27.20 to $27.63 (weighted average reported). The filer offers to provide full trade-by-trade details on request.
• Footnote: The sales were made pursuant to a Rule 10b5-1 trading plan adopted December 16, 2025, to satisfy estimated tax obligations related to vesting restricted stock units.
• Shares owned after the transaction: not provided in the excerpt of the filing.
• Timing note: The Form 4 was filed five days after the transaction (filed 2026-07-07 for a 2026-07-02 trade); Form 4s are generally due within two business days, so this filing appears delayed.

Context
Sales under 10b5-1 plans are common for covering tax obligations tied to equity awards and are typically considered routine rather than a signal of insider sentiment. For retail investors, purchases by insiders usually carry more immediate informational weight than routine sales; this filing documents a tax-related disposition rather than an opportunistic market buy.